Aeterna zentaris inc. stock
Stock Info — Aeterna Zentaris Our Company About Us Leadership Team Board of Directors Locations Contact Us Products Macimorelin News & Media Press Releases Investors Corporate Profile Press Releases Analyst Coverage Events & Presentations Corporate Governance Financials & Filings Stock Info Annual Reports Contact Us Contact AEterna Zentaris Inc. (AEZS) SEC Filings - NASDAQ.com Mar 19, 2020 · AEterna Zentaris Inc. (AEZS) SEC Filings - Get realtime SEC filings forAEterna Zentaris Inc. and all the companies you research at NASDAQ.com Aeterna Zentaris Inc. Common Stock (AEZS) News Headlines ...
Profile for AEterna Zentaris Inc. (AEZS). « Back to company index. AEZS Chatter Timeline. Stock Ticker for AEZS. Most Active Tweeters for AEZS. User, Tweets.
Check out our AEZS stock analysis, current AEZS quote, charts, and historical prices for Aeterna Zentaris Inc stock Aeterna Zentaris Inc. (AEZS) Stock Quote | Price Chart ... View a financial market summary for AEZS including stock price quote, trading volume, volatility, options volume, statistics, and other important company data related to AEZS (Aeterna Zentaris Inc.) stock. AEZS Stock Quote - Aeterna Zentaris Inc. Common Stock ... Stock quote for Aeterna Zentaris Inc. Common Stock Common Stock (AEZS) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.
AEterna Zentaris Inc. [AEZS] | AEterna Zentaris Inc. Stock ...
17 Jan 2018 AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) investors are busy throwing a party today following the news that tiny drug maker has sold its U.S. AEterna Zentaris Inc $ 0.5 -0.02 (-3.12%). On watch. Volume: 105,232. Avg Vol ( 1m):. 295,105. Market Cap $:. 11.67 Mil. Enterprise Value $:. 1.88 Mil. P/E (TTM):.
Description AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in development and commercialization of novel pharmaceutical therapies, drug development activities and
AEterna Zentaris Inc. [AEZS] | AEterna Zentaris Inc. Stock ... AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in development and commercialization of novel pharmaceutical therapies, drug development activities and promotion of products for others in oncology, endocrinology and women's health. All News for AEZS : AEterna Zentaris Inc. - Zacks.com Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options. by Zacks Equity Research Published on January 29,2019 . Investors need to pay close attention to Aeterna Zentaris (AEZS) stock AEterna Zentaris Inc (AEZS) Quote | Morningstar Learn about AEZS with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free trial to Morningstar Premium to unlock our take on AEZS. Aeterna Zentaris Inc. Common Stock (AEZS) Real-Time Stock ...
AEterna Zentaris Inc (AEZS) Last: 0.496, Change: -0.016 (-3.12%), Volume: 105,232. Put volume: 0 • Call volume: 20 • Put:Call Ratio: 0.00
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used AEZS Stock Price, Forecast & News (AEterna Zentaris) Here are some recent quotes from research analysts about AEterna Zentaris stock: 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Aclaris Therapeutics (NASDAQ:ACRS), AEterna Zentaris Inc ...
Aeterna Zentaris Inc. (AEZS) Stock Dividend Data. AEZS Stock Dividend Data. Dividend Yield Dividend Yield. Dividend yield is the relation between a stock’s annual dividend payout and its current stock price. Click here to learn more. 0.00% Average Yield: N/A ANNUALIZED PAYOUT Annualized Payout. AEZS Aeterna Zentaris Inc. Stock Quote - FINVIZ.com Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used